Related Experiment Videos
[Recurrence of pulmonary sarcoidosis]
E Puścińska1, D Zych, L Pawlicka
1Kliniki Chorób Płuc, Instytutu Gruźlicy i Chorób Płuc w Warszawie.
Pneumonologia I Alergologia Polska
|January 1, 1995
Summary
Relapse of pulmonary sarcoidosis occurred in 9% of patients treated with steroids, with some experiencing a second relapse. Steroid treatment for sarcoidosis can lead to disease recurrence after therapy completion.
Area of Science:
- Pulmonology
- Clinical Medicine
- Rheumatology
Background:
- Pulmonary sarcoidosis is a multisystem inflammatory disease.
- Steroid therapy is a common treatment for sarcoidosis.
- Understanding relapse patterns is crucial for long-term management.
Purpose of the Study:
- To investigate the incidence and characteristics of relapse in patients with pulmonary sarcoidosis treated with steroids.
- To analyze factors associated with disease recurrence after initial treatment.
Main Methods:
- Retrospective analysis of 462 patients with pulmonary sarcoidosis treated with steroids from a cohort of 2021 registered patients.
- Data collection included treatment initiation criteria, disease stage, extra-pulmonary involvement, and relapse occurrences.
- Follow-up duration ranged from 6 months to 6 years post-treatment.
Main Results:
- A relapse rate of 9% (42 out of 462 patients) was observed after completing steroid treatment.
- Relapse occurred between 6 months and 6 years after treatment cessation.
- Extra-pulmonary lesions were present in 38% of patients who relapsed.
- Second relapses were noted in 4 cases, with most patients achieving improvement or stabilization after subsequent treatment.
Conclusions:
- Pulmonary sarcoidosis patients treated with steroids have a significant risk of relapse.
- The presence of extra-pulmonary lesions may be associated with a higher risk of relapse.
- Long-term monitoring is essential for managing sarcoidosis recurrence.